Coya Therapeutics Shakes Up Board Ahead of Key ALS Trial Readout
Event summary
- Founder Howard Berman steps down as Executive Chairman after guiding Coya through IPO and Phase 2B trial initiation.
- Mark H. Pavao, with 30+ years in biopharma commercialization, joins board to fill vacancy.
- Pavao's expertise in neuroscience commercialization seen as critical ahead of COYA 302's ALS trial readout.
- Transition part of planned leadership succession begun in November 2024.
- COYA 302 Phase 2B ALSTARS trial (NCT07161999) approaching critical data readout.
The big picture
This board transition positions Coya for its next growth phase as it moves from clinical development to potential commercialization. The appointment of a seasoned commercial executive suggests preparation for positive trial results and regulatory milestones. In the competitive neurodegenerative space, governance shifts like this often precede critical inflection points in company valuation and strategic direction.
What we're watching
- Trial Timing
- How the pace of COYA 302's Phase 2B data readout will impact Pavao's commercialization strategy.
- Leadership Transition
- Whether Berman's departure signals full operational handoff or potential future advisory role.
- Commercial Readiness
- The extent to which Pavao's neuroscience experience accelerates COYA 302's path to market.
Related topics